#obesity-drug-market
#obesity-drug-market

Medicine

How well GLP-1 weight loss drugs work may depend on your genetics

Psychology

What Weight-Loss Drugs Reveal About How We Judge Effort

Visible struggle in weight loss is often misinterpreted as greater effort, while underlying biological and psychological factors play a significant role.

fromABC7 New York

Medicine

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

Eli Lilly's orforglipron, branded as Foundayo, is a new FDA-approved weight-loss pill expected to be available soon.

Medicine

US approves new oral weight-loss pill developed by Eli Lilly

FDA approved orforglipron, a new oral weight-loss medication by Eli Lilly, offering an alternative to injectable GLP-1 treatments.

New light shed on who benefits most from weight-loss jabs

Genetic variations in appetite and digestion can enhance weight loss effectiveness of drugs like Wegovy and Mounjaro.

How well GLP-1 weight loss drugs work may depend on your genetics

Genetic variations can explain why some individuals do not respond to weight-loss drugs like Wegovy and Zepbound.

Psychology

What Weight-Loss Drugs Reveal About How We Judge Effort

Visible struggle in weight loss is often misinterpreted as greater effort, while underlying biological and psychological factors play a significant role.

fromABC7 New York

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

Eli Lilly's orforglipron, branded as Foundayo, is a new FDA-approved weight-loss pill expected to be available soon.

US approves new oral weight-loss pill developed by Eli Lilly

FDA approved orforglipron, a new oral weight-loss medication by Eli Lilly, offering an alternative to injectable GLP-1 treatments.

more#weight-loss

Gen Z wants their job to cover GLP-1 weight-loss drugs, survey suggests

A new ZipHealth survey of over 1,000 workers found that nearly half (47%) of Gen Z said GLP-1 coverage would affect their choices between two similar jobs.

Healthcare

Artificial intelligence

fromFuturism

Why Is the New York Times Laundering the Reputation of a Sleazy AI Startup That's Selling GLP-1s via a Dishonest Dumpster Fire of Fake Doctors, Phony Before-and-After Pictures, a Warning From the FDA, and Other Glaring Red Flags?

Medvi, an AI-driven pharmaceutical company, is reportedly on track for $2 billion in sales with minimal human staff, raising concerns about its legitimacy.

The FDA approves a new obesity pill, giving patients another option

We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.

US news

Wegovy's new pricing could save you $1,200-but it's not for everyone

Novo Nordisk launched a subscription program for Wegovy to reduce cost uncertainty and improve access to obesity treatment.

Medicine

Wegovy just became available in an unexpected place

NYC startup

Wegovy's new pricing could save you $1,200-but it's not for everyone

Novo Nordisk launched a subscription program for Wegovy to reduce cost uncertainty and improve access to obesity treatment.

Medicine

Wegovy just became available in an unexpected place

more#wegovy

Wave Life Sciences Slips as Obesity Data Fails to Convince

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.

Cancer

#genetics

Genetics may help explain why results from weight-loss jabs vary, say scientists

Genetic variations in gut hormone pathways may explain differing responses to weight-loss medications like GLP1 receptor agonists.

2 days ago

Why obesity drugs work better for some people: these genes hold clues

Genetic variants influence individual responses to obesity drugs, affecting weight loss and side effects.

Genetics may help explain why results from weight-loss jabs vary, say scientists

Genetic variations in gut hormone pathways may explain differing responses to weight-loss medications like GLP1 receptor agonists.

2 days ago

Why obesity drugs work better for some people: these genes hold clues

Genetic variants influence individual responses to obesity drugs, affecting weight loss and side effects.

Marketing

Ro CEO on the next phase of the Ozempic boom

Medicine

A new weight loss pill is here and it could reshape the GLP-1 market

5 days ago

A 59-year-old man lost 25 pounds on Foundayo, the new GLP-1 weight-loss pill

Eli Lilly's Foundayo, the first once-daily GLP-1 pill for weight loss, has been approved by the FDA.

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals.

Eli Lilly's Foundayo, a new weight loss pill, offers flexible dosing and outperforms competitors in weight loss and health metrics.

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution is driving biopharma M&A strategies, with companies like Viking Therapeutics and Structure Therapeutics as prime acquisition targets.

Science

The Weight-Loss Drug RevolutionShots, Pills and the Science behind the Hype

2 weeks ago

Marketing

Ro CEO on the next phase of the Ozempic boom

Medicine

A new weight loss pill is here and it could reshape the GLP-1 market

5 days ago

A 59-year-old man lost 25 pounds on Foundayo, the new GLP-1 weight-loss pill

Eli Lilly's Foundayo, the first once-daily GLP-1 pill for weight loss, has been approved by the FDA.

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals.

Eli Lilly's Foundayo, a new weight loss pill, offers flexible dosing and outperforms competitors in weight loss and health metrics.

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution is driving biopharma M&A strategies, with companies like Viking Therapeutics and Structure Therapeutics as prime acquisition targets.

Science

The Weight-Loss Drug RevolutionShots, Pills and the Science behind the Hype

Exercise

Strength persists after a mid-life course of obesity drugs

Healthcare

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

Media industry

How weight-loss jabs are changing the way we spend money

fromHarvard Gazette

Health

Pricey blockbuster GLP-1s are costing users - and most of the rest of us, too - Harvard Gazette

Public health

Are obesity drugs causing a severe complication? What the science says

Use of GLP-1 drugs has been linked to rising reports of acute pancreatitis, including rare fatal cases, prompting strengthened regulatory warnings in multiple countries.

The GLP-1 saga is only getting juicier and messier

The FDA warned Novo Nordisk about failing to disclose risks and report deaths linked to semaglutide, while GLP-1 drugs surge in popularity for diabetes and weight loss despite unapproved market alternatives.

Exercise

Strength persists after a mid-life course of obesity drugs

Healthcare

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

Media industry

How weight-loss jabs are changing the way we spend money

fromHarvard Gazette

Health

Pricey blockbuster GLP-1s are costing users - and most of the rest of us, too - Harvard Gazette

Public health

Are obesity drugs causing a severe complication? What the science says

The GLP-1 saga is only getting juicier and messier

more#glp-1-drugs

Eli Lilly Falls 5% - FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares

The primary catalyst today is investor anxiety around the timing and outcome of the FDA's expected decision on orforglipron, Lilly's oral GLP-1 obesity pill. Lilly submitted orforglipron for obesity approval in the U.S. and Japan, and for both obesity and type 2 diabetes in the EU, with CEO David Ricks citing the submission as a "key 2025 milestone." An April decision window has been widely discussed, and markets are pricing in meaningful uncertainty around both timing and label scope.

Business

#glp-1-medications

Medicine

The Dangerous Allure of Compounded GLP-1 Drugs

Alternative medicine

Understanding and Navigating Weight Loss Medications

Healthcare

What Eli Lilly's new employer platform could mean for access to weight-loss drugs

Health

New study of 77,000 patients reveals the hard truth about GLP1s

Mental health

GLP-1 obesity drugs can complicate life for people with disordered eating

Widespread availability and effectiveness of GLP-1 weight-loss drugs, often obtained online with little screening, can worsen or trigger eating disorders and cause dangerous health effects.

fromScienceDaily

2 weeks ago

What happens after Ozempic shocked researchers

Stopping GLP-1 medications like Ozempic does not typically lead to significant weight regain, as many patients switch treatments or restart therapy.

The Dangerous Allure of Compounded GLP-1 Drugs

Compounded GLP-1 medications can be unsafe and unregulated, leading to serious health risks like acute liver failure.

Alternative medicine

Understanding and Navigating Weight Loss Medications

GLP-1 and semaglutide medications effectively reduce obesity but require medical guidance and are not standalone solutions to weight management.

Healthcare

What Eli Lilly's new employer platform could mean for access to weight-loss drugs

Health

New study of 77,000 patients reveals the hard truth about GLP1s

Mental health

GLP-1 obesity drugs can complicate life for people with disordered eating

fromScienceDaily

2 weeks ago

What happens after Ozempic shocked researchers

Stopping GLP-1 medications like Ozempic does not typically lead to significant weight regain, as many patients switch treatments or restart therapy.

more#glp-1-medications

Is a new weight-loss drug making people fall out of love?

Retatrutide, an experimental weight-loss drug, may cause emotional flattening and affect relationships by dampening the brain's reward system.

#fda-approval

Medicine

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval

Medicine

FDA approves higher-dose version of Wegovy shots

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval

Eli Lilly's orforglipron received FDA approval as a weight loss treatment, showing significant weight loss in clinical trials.

Medicine

FDA approves higher-dose version of Wegovy shots

FDA Approves Eli Lilly's GLP-1 Pill

The FDA approved Foundayo, a new daily obesity pill by Eli Lilly, expanding options for weight loss treatments alongside injectable GLP-1 medications.

Medicine

GLP-1 drugs don't work for everyone. But personalized obesity care in the future might

fromWIRED

FDA Approves Eli Lilly's GLP-1 Pill

The FDA approved Foundayo, a new daily obesity pill by Eli Lilly, expanding options for weight loss treatments alongside injectable GLP-1 medications.

Medicine

GLP-1 drugs don't work for everyone. But personalized obesity care in the future might

more#obesity

NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokes

NHS England will provide weight-loss drugs to over 1 million people to reduce heart attack and stroke risks.

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

Novo Nordisk cut prices on Wegovy and Ozempic by up to 48% in India due to market pressures from generic semaglutide.

Healthcare

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

6 days ago

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

Novo Nordisk cut prices on Wegovy and Ozempic by up to 48% in India due to market pressures from generic semaglutide.

Healthcare

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Inside Health - What are the side effects of weight loss drugs? - BBC Sounds

Weight loss drugs were used by over 1.5 million UK adults in 2024–25 and can cause side effects including nausea and painful gallstones.

'I thought I was going to die' - Woman calls for tighter weight-loss jabs checks

Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."

Health

Healthcare

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Novo Nordisk's stock dropped 22% weekly and 56% yearly after CagriSema trial failure and announced price cuts on flagship drugs, causing analyst downgrades and declining Reddit sentiment.

Marketing

fromDigiday

GLP-1 draws pharma advertisers to double down on the Super Bowl

Pharmaceutical and healthcare brands are heavily advertising GLP-1 and related products during the Super Bowl despite potential regulatory threats to pharma advertising.

Business

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Concentrated exposure to GLP-1 leaders drove PPH's gains, but rising competition, pricing pressure, and concentration risk threaten future performance.

#glp-1-receptor-agonists

Can weight-loss pills replace injectables? What the science says

Oral anti-obesity pills based on GLP-1 receptor agonists are entering the market, offering needle-free alternatives to injectable weight-loss drugs, though they produce less weight loss than injections.

Medicine

Weight loss drugs may stop people getting addicted to drugs and alcohol, study finds

Medicine

Head-to-head trial pitting Eli Lilly's oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills

Medicine

The next wave of GLP-1 drugs are comingand they're stronger than Wegovy and Zepbound

Can weight-loss pills replace injectables? What the science says

Medicine

Weight loss drugs may stop people getting addicted to drugs and alcohol, study finds

Medicine

Head-to-head trial pitting Eli Lilly's oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills

more#glp-1-receptor-agonists

Medicine

The next wave of GLP-1 drugs are comingand they're stronger than Wegovy and Zepbound

The Guardian view on weight-loss jabs and addiction: there is too much moralising about these remarkable medicines | Editorial

Weight-loss drugs show promise in reducing addiction risk, suggesting they may address shared biological mechanisms between food and drug cravings in the brain.

#weight-loss-injections

Public health

One in seven using drugs not licensed for weight loss as 1.6m in UK now on them

Public health

Could weight-loss jabs be behind rising gallbladder removals?

Public health

One in seven using drugs not licensed for weight loss as 1.6m in UK now on them

more#weight-loss-injections

Public health

Could weight-loss jabs be behind rising gallbladder removals?

#semaglutide

fromIndependent

Medicine

Luke O'Neill: Weight-loss drugs have been linked to sudden blindness, so how worried should you be?

Medicine

Hims & Hers removes a knock-off weight loss drug days after introducing it

fromIndependent

Medicine

Luke O'Neill: Weight-loss drugs have been linked to sudden blindness, so how worried should you be?

Medicine

Hims & Hers removes a knock-off weight loss drug days after introducing it

Revealed: The massive HSE spend on weight-loss jabs like Ozempic - and which area is availing of the drugs most

Public healthcare spending on Ozempic and similar weight-loss injections exceeded €200 million in under three years, funded by taxpayers.

Weight-loss jab could be made for $3 a month, study finds

New research, published as a pre-print, suggests that semaglutide could be mass produced for $3 (about 2.35) for a monthly dose in its injectable form. Newer formulations, taken as a pill rather than an injection, could be made for about $16 a month.

Medicine